Evidence map›Paper›PMID 33354232›Full record

ArticleTherapeutic advances in musculoskeletal disease2020

Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis.

Raul Castellanos-Moreira, Sebastian C Rodriguez-Garcia, Sonia Cabrera-Villalba, María José Gomara, Georgina Salvador, Virginia Ruiz-Esquide, Julio Ramirez, Jose Inciarte-Mundo, Rosa Morla, Cristina Garcia-Moreno and 5 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Raul Castellanos-MoreiraArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-4104-4101
Sebastian C Rodriguez-GarciaArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Sonia Cabrera-VillalbaArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
María José GomaraUnit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas (IQAC-CSIC), Barcelona, Spain.
Georgina SalvadorRheumatology Department, University Hospital Mutua Tarrasa, Barcelona, Spain.
Virginia Ruiz-EsquideArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Julio RamirezArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-7047-8056
Jose Inciarte-MundoArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Rosa MorlaArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Cristina Garcia-MorenoUnit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas (IQAC-CSIC), Barcelona, Spain.
Andrea CuervoArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Jose A Gómez-PuertaArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Juan D CañeteArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Isabel HaroUnit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas (IQAC-CSIC), Barcelona, Spain.
Raimon SanmartiArthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Villarroel 170, Barcelona, 08036, Spain.ORCID https://orcid.org/0000-0002-8864-3806
Hospital Clínic de Barcelona · ESConsejo Superior de Investigaciones Científicas · ESUniversity Hospital Mútua de Terrassa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA restricted response against citrullinated peptides/proteins, with less isotype usage, has been found in palindromic rheumatism (PR) in comparison with rheumatoid arthritis (RA). We hypothesized that this different antibody response may be observed for other post-translational modified proteins. We compared the prevalence and isotype usage of two specificities of anti-carbamylated peptide/protein antibodies (Anti-CarP) in patients with PR and RA.

methodsCross-sectional study including 54 patients with pure PR and 53 patients with RA, matched by sex, age, disease duration and ACPA. Anti-CarP specificities were determined by home-made enzyme-linked immunosorbent assay tests using a synthetic chimeric fibrin/filaggrin homocitrullinated peptide (CFFHP) and fetal calf serum (FCS) homocitrullinated protein as antigens. IgG, IgA and IgM isotypes were measured.

resultsAnti-CarP were positive (CFFHP or FCS) in 24% and 64% of patients with PR and RA, respectively (

conclusionAnti-CarP are found in patients with PR but in a lower proportion and with a different isotype usage from in RA, suggesting a distinct B cell response to homocitrullinated antigens in PR.

Indexed as

ACPAAnti-CarPautoantibodiesB cellspalindromic rheumatismrheumatoid arthritis

Identifiers

PMID33354232
PMCPMC7734508
OpenAlexW3111830066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.